Business Context and Reporting Period
This Form 8-K Current Report from Syndax Pharmaceuticals, Inc. (SNDX) covers events occurring on June 10, 2026, specifically the Company's 2026 Annual Meeting of Stockholders. The filing details the approval of new equity incentive plans and the results of shareholder votes on director elections and executive compensation.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity plan approvals and voting results.
Material Changes and Corporate Actions
- 2026 Equity Incentive Plan Approval: Stockholders approved the 2026 Equity Incentive Plan, which became effective on June 10, 2026. This plan replaces the expired 2015 Omnibus Incentive Plan (expired March 6, 2026).
- Share Reserve: The plan reserves 7,200,000 shares of common stock for new awards.
- Recycling Provision: Shares from unvested or cancelled awards under the 2015 Plan will become available for the 2026 Plan.
- 2026 Employee Stock Purchase Plan (ESPP) Approval: Stockholders approved the 2026 ESPP, effective June 10, 2026, as the successor to the 2015 ESPP.
- Share Rollover: Shares available under the 2015 ESPP will not roll over to the 2026 ESPP.
- Director Election Results:
- Pierre Legault: Received 37,294,888 votes "For" and 21,467,975 "Withheld" (approx. 63.5% support).
- Michael A. Metzger: Received 58,113,110 votes "For" and 649,753 "Withheld" (approx. 98.9% support).
- Executive Compensation Vote: The advisory vote on executive compensation passed with 55,688,039 "For" votes versus 2,985,350 "Against" votes.
- 2026 Plan Vote Split: The approval of the 2026 Equity Incentive Plan was closely contested, with 33,333,263 "For" votes and 25,392,051 "Against" votes.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or specific risk factors beyond the standard incorporation by reference of the full plan texts. The primary operational change is the transition to new equity compensation structures to retain employees and directors.
Investor Verification Checklist
- Verify the total number of shares authorized under the new 2026 Equity Incentive Plan (7.2 million) and the specific recycling mechanics for the 2015 Plan.
- Review the full text of the 2026 Plan (Exhibit 10.1) and 2026 ESPP (Exhibit 10.2) for specific vesting schedules and eligibility criteria.
- Note the significant "Against" vote (approx. 43%) on the 2026 Equity Incentive Plan, which may indicate shareholder concerns regarding dilution or plan terms.
- Confirm that no shares from the 2015 ESPP were carried forward to the new plan, potentially limiting immediate availability for employee purchases.